Birgit Luber

Prof. Birgit Luber holds a professorship in Pathology at the TUM School of Medicine and Health, Technische Universität München. Her research focuses on molecular mechanisms of gastric cancer, particularly HER2 pathway biology, targeted therapy response prediction, and biomarker discovery. She leads the VARIANZ study analyzing HER2 testing discrepancies and their clinical implications, emphasizing translational research bridging pathology and oncology.

Her work combines systems medicine approaches with advanced techniques like MALDI imaging mass spectrometry and phosphoprotein profiling to dissect metabolic and genetic heterogeneity in tumors. Key research themes include therapy resistance mechanisms, precision oncology, and multimodal biomarker validation. Over 40 peer-reviewed articles since 1991 demonstrate sustained contributions to gastric cancer pathophysiology and clinical diagnostics.

Her studies integrate cell line models, patient tissue analyses, and computational modeling to address challenges in targeted therapy efficacy prediction. Collaborations span clinical trials, diagnostic standardization, and interdisciplinary systems biology initiatives.